Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-arm Phase II-study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status

NCT07803848 is registered in ClinicalTrials.gov with AIO-Studien-gGmbH as lead sponsor.

NCT NCT07803848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07803848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-arm Phase II-study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status
Lead sponsor
AIO-Studien-gGmbH
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2025
Completion date
December 31, 2028
Enrollment
57 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

small-cell lung cancer